Email Us Here

Themis Bioscience: Chikungunya Vaccine Development Towards Phase III Trials Boosted by Innovate UK

The further development of a promising Chikungunya vaccine candidate by Themis Bioscience is now supported with 3 Mio. GBP by the United Kingdom's innovation agency, Innovate UK.